RetaMaps

Primary Health & Wellness: Stacey Simmons, NP

Primary Health & Wellness: Stacey Simmons, NP · 2256 Northlake Parkway · Tucker, GA 30084

4.9· 52 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • Medically supervised weight loss

About this practice

Primary Health & Wellness, listed with Stacey Simmons, NP, is a newly developed clinic in Tucker, Georgia, that its website says is committed to compassionate, patient-centered care. Per the site, services include treatment of minor illnesses and non-emergent injuries, IV hydration, and physical exams such as DOT, employment, school and sports exams. It names Cydni Martin, PA-C, among its clinicians, and telehealth is listed. Google shows 52 reviews averaging 4.9 stars since 2024, nine in the past year, with reviewers most often mentioning the staff and the providers' knowledge, and six mentioning wait times.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.9
Google rating · 52 reviews
9
reviews in the past year (avg ★ 4.4)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-05. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.9 across 52 Google reviews. Of the 52 reviews we analyzed, 50 (96%) are positive (4–5★) and 1 (2%) are negative (1–2★).

What patients like

  • Friendly, helpful staff26 reviews
  • Knowledgeable, professional providers19 reviews
  • Feeling listened to9 reviews
  • Clean, comfortable office7 reviews

Common complaints

Very few complaints — only 1 negative review, with no recurring theme.

5★
50
4★
0
3★
1
2★
1
1★
0

Most recent Google reviews

Jamarcus P.★★★★★2026-08-26

Exceptional service! The staff was friendly, welcoming, and provided fast, efficient service. Great experience from start to finish!

Bre★★★★★2026-07-29

Good experience but learn to answer you’re phones thanks!

Destiny L.★★★★★2026-06-07

Never coming back here. Ramsy has a nasty attitude and lacks professionalism. Also was lied to by the doctor.

Edward H.★★★★★2026-03-11

Office was amazing, women was beautiful pleasant kind friendly, and Stacey Simmons was very informative and knew her job. I will recommend her a million times over. Thanks

Sean P.★★★★★2026-02-26

The office was very clean and welcoming. The staff were also friendly and welcoming. The front staff knew what they were doing and got me checked in fast. I was seen by Ms. Simmons who was very punctual, knowledgeable, and kind. I felt that Ms. Simmons really cared about my situation and what was going on and had my best interests in mind. Ms. Simmons Listened to everything I had to say during my visit.

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Clinicians

  • Primary Health & Wellness: Stacey Simmons, NP

Nearby providers in Tucker

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs